Independent
Tenure on this board
7.9 yrs
Also a director at
Editas Medicine Inc (EDIT)
Meeting calendar
HALO · Annual meeting · Tuesday, May 5, 2026
Halozyme Therapeutics Inc
2 nominees · 3 ballot items.
Election of two Class I directors; advisory (non-binding) approval of executive compensation (say-on-pay); ratification of Ernst & Young LLP as independent registered public accounting firm for 2026.
Market cap
$9.2B
1Y TSR
+31.5%
Board grade
C+
Record date
Mar 9, 2026
Filing
DEF 14A
Meeting concluded · May 5, 2026
Follow how the vote landed and what changed on Halozyme Therapeutics Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Election of Directors
ManagementBoard: FORElect two Class I directors (Bernadette Connaughton and Matthew L. Posard) to serve three-year terms until 2029.
- 2
Advisory (Non-Binding) Vote on Executive Compensation (Say-on-Pay
ManagementBoard: FORNon-binding advisory approval of the compensation of the Named Executive Officers as disclosed in the proxy statement.
More detail
This management proposal seeks a non-binding advisory approval of the Company’s executive compensation program as disclosed in the proxy statement (CD&A, tables, and narrative). Management is asking shareholders to endorse its compensation practices, which emphasize alignment between executive pay and long-term stockholder value via a mix of base salary, annual cash incentives tied to corporate performance metrics, and long-term equity incentives heavily weighted to performance-vesting PSUs and stock options. The Board recommends a FOR vote, citing strong 2025 financial results, robust governance practices (clawback policy, no single-trigger CIC payouts, stock ownership guidelines), and significant stockholder support in prior say-on-pay votes. A FOR vote is non-binding but signals shareholder support; a substantial vote against could prompt the Board and Compensation Committee to engage with stockholders and consider changes.
- 3
Ratification of Selection of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify Ernst & Young LLP as Halozyme’s independent registered public accounting firm for fiscal year ending December 31, 2026.
Director elections
Nominees on the ballot2
Independent
Tenure on this board
13.3 yrs
Also a director at
Nautilus Biotechnology Inc (NAUT)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | BlackRock, Inc. | 6.9% | 8,229,039 | $532M |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 4.4% | 5,271,218 | $341M |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4.4% | 5,249,206 | $339M |
| 4 | STATE STREET CORP | 4.2% | 4,937,854 | $319M |
| 5 | BlackRock, Inc. | 3.0% | 3,512,989 | $227M |
| 6 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 2.1% | 2,525,975 | $163M |
| 7 | Boston Partners | 2.1% | 2,490,929 | $161M |
| 8 | Invesco Ltd. | 2.0% | 2,357,997 | $152M |
| 9 | SNYDER CAPITAL MANAGEMENT L P | 2.0% | 2,323,077 | $150M |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 1.7% | 2,073,937 | $134M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Halozyme Therapeutics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Apogee Therapeutics IncAPGE
Special meeting·Aug 11, 2026·$10.1B
Amneal Pharmaceuticals IncAMRX
Special meeting·Jul 31, 2026·$5.8B
Doximity IncDOCS
Annual meeting·Aug 27, 2026·$4.1B
Haemonetics CorpHAE
Annual meeting·Jul 24, 2026·$3.6B
Organon & CoOGN
Special meeting·Jul 23, 2026·$3.5B
Jazz Pharmaceuticals PLCJAZZ
Annual meeting·Jul 23, 2026·$15.2B
Reference
Frequently asked questions
- When is the Halozyme Therapeutics Inc 2026 annual meeting?
- Halozyme Therapeutics Inc (HALO) holds its 2026 annual shareholder meeting on Tuesday, May 5, 2026.
- What is the record date for the Halozyme Therapeutics Inc 2026 meeting?
- The record date for the Halozyme Therapeutics Inc 2026 meeting is Monday, March 9, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Halozyme Therapeutics Inc's 2026 meeting?
- The board is presenting 2 director nominees at the Halozyme Therapeutics Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Halozyme Therapeutics Inc 2026 meeting?
- Shareholders will vote on 3 proposals at the Halozyme Therapeutics Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.